_id
69104d3fccc777a4e85d52ca
Ticker
CGON
Name
CG Oncology, Inc. Common stock
Exchange
NASDAQ
Address
400 Spectrum Center Drive, Irvine, CA, United States, 92618
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://cgoncology.com
Description
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Last Close
40.14
Volume
772239
Current Price
40.04
Change
1.35
Last Updated
2026-01-02T11:16:11.288Z
Image
data:image/webp;base64,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
Ipo Date
2024-01-25T00:00:00.000Z
Market Cap
3349259776
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.990923076923077
Sentiment Sources
13
Rating
4.4
Target Price
70.7143
Strong Buy
5
Buy
4
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
1666000
Cost Of Revenue
1577000
Gross Profit
89000
Operating Expenses
51218000
Operating Income
-51129000
Interest Expense
-
Pretax Income
-43808000
Net Income
-43808000
Eps
-0.5709390908029569
Dividends Per Share
-
Shares Outstanding
80666179
Income Tax Expense
-
EBITDA
-43392000
Operating Margin
-3068.9675870348137
Total Other Income Expense Net
7321000
Cash
45145000
Short Term Investments
635118000
Receivables
515000
Inventories
1501000
Total Current Assets
695790000
Property Plant Equipment
19532000
Total Assets
729913000
Payables
9193000
Short Term Debt
912000
Long Term Debt
3000000
Total Liabilities
42270000
Equity
687643000
Bs_currency_symbol
USD
Depreciation
416000
Change In Working Capital
-2873000
Cash From Operations
-38894000
Capital Expenditures
97000
Cash From Investing
15045000
Cash From Financing
54370000
Net Change In Cash
30521000
Cf_currency_symbol
USD
PE
-
PB
4.467809937772944
ROE
-6.37074761176948
ROA
-6.001811174756443
FCF
-38991000
Fcf Percent
-23.403961584633855
Piotroski FScore
1
Health Score
30
Deep Value Investing Score
3
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
4.5
Net Net Investing Score
1
Quality Investing Score
2.5
Value Investing Score
3
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
1666000
Quarters > 0 > income Statement > cost Of Revenue
1577000
Quarters > 0 > income Statement > gross Profit
89000
Quarters > 0 > income Statement > operating Expenses
51218000
Quarters > 0 > income Statement > operating Income
-51129000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-43808000
Quarters > 0 > income Statement > net Income
-43808000
Quarters > 0 > income Statement > eps
-0.5709390908029569
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
76729726
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-43392000
Quarters > 0 > income Statement > operating Margin
-3068.9675870348137
Quarters > 0 > income Statement > total Other Income Expense Net
7321000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
45145000
Quarters > 0 > balance Sheet > short Term Investments
635118000
Quarters > 0 > balance Sheet > receivables
515000
Quarters > 0 > balance Sheet > inventories
1501000
Quarters > 0 > balance Sheet > total Current Assets
695790000
Quarters > 0 > balance Sheet > property Plant Equipment
19532000
Quarters > 0 > balance Sheet > total Assets
729913000
Quarters > 0 > balance Sheet > payables
9193000
Quarters > 0 > balance Sheet > short Term Debt
912000
Quarters > 0 > balance Sheet > long Term Debt
3000000
Quarters > 0 > balance Sheet > total Liabilities
42270000
Quarters > 0 > balance Sheet > equity
687643000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-43808000
Quarters > 0 > cash Flow > depreciation
416000
Quarters > 0 > cash Flow > change In Working Capital
-2873000
Quarters > 0 > cash Flow > cash From Operations
-38894000
Quarters > 0 > cash Flow > capital Expenditures
97000
Quarters > 0 > cash Flow > cash From Investing
15045000
Quarters > 0 > cash Flow > cash From Financing
54370000
Quarters > 0 > cash Flow > net Change In Cash
30521000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.5709390908029569
Quarters > 0 > ratios > PB
4.467809937772944
Quarters > 0 > ratios > ROE
-6.37074761176948
Quarters > 0 > ratios > ROA
-6.001811174756443
Quarters > 0 > ratios > FCF
-38991000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-23.403961584633855
Quarters > 0 > health Score
30
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
156000
Quarters > 1 > income Statement > gross Profit
-156000
Quarters > 1 > income Statement > operating Expenses
48585000
Quarters > 1 > income Statement > operating Income
-48741000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-41426000
Quarters > 1 > income Statement > net Income
-41426000
Quarters > 1 > income Statement > eps
-0.5434569500457641
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
76226829
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-41270000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
7315000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
14624000
Quarters > 1 > balance Sheet > short Term Investments
646428000
Quarters > 1 > balance Sheet > receivables
562000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
673030000
Quarters > 1 > balance Sheet > property Plant Equipment
1218000
Quarters > 1 > balance Sheet > total Assets
701445000
Quarters > 1 > balance Sheet > payables
7125000
Quarters > 1 > balance Sheet > short Term Debt
288000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
31087000
Quarters > 1 > balance Sheet > equity
670358000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-41426000
Quarters > 1 > cash Flow > depreciation
156000
Quarters > 1 > cash Flow > change In Working Capital
8663000
Quarters > 1 > cash Flow > cash From Operations
-27959000
Quarters > 1 > cash Flow > capital Expenditures
14000
Quarters > 1 > cash Flow > cash From Investing
1407000
Quarters > 1 > cash Flow > cash From Financing
-296000
Quarters > 1 > cash Flow > net Change In Cash
-26848000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.5434569500457641
Quarters > 1 > ratios > PB
4.552973535275181
Quarters > 1 > ratios > ROE
-6.17968309470462
Quarters > 1 > ratios > ROA
-5.905808723420939
Quarters > 1 > ratios > FCF
-27973000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
38
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
52000
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
52000
Quarters > 2 > income Statement > operating Expenses
42256000
Quarters > 2 > income Statement > operating Income
-42204000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-34452000
Quarters > 2 > income Statement > net Income
-34452000
Quarters > 2 > income Statement > eps
-0.45219944589161015
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
76187621
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-42180000
Quarters > 2 > income Statement > operating Margin
-81161.53846153847
Quarters > 2 > income Statement > total Other Income Expense Net
7752000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
41472000
Quarters > 2 > balance Sheet > short Term Investments
646962000
Quarters > 2 > balance Sheet > receivables
345000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
701192000
Quarters > 2 > balance Sheet > property Plant Equipment
1297000
Quarters > 2 > balance Sheet > total Assets
728181000
Quarters > 2 > balance Sheet > payables
6731000
Quarters > 2 > balance Sheet > short Term Debt
255000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
23423000
Quarters > 2 > balance Sheet > equity
704758000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-34452000
Quarters > 2 > cash Flow > depreciation
24000
Quarters > 2 > cash Flow > change In Working Capital
469000
Quarters > 2 > cash Flow > cash From Operations
-29277000
Quarters > 2 > cash Flow > capital Expenditures
16000
Quarters > 2 > cash Flow > cash From Investing
-186769000
Quarters > 2 > cash Flow > cash From Financing
450000
Quarters > 2 > cash Flow > net Change In Cash
-215596000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.45219944589161015
Quarters > 2 > ratios > PB
4.328510417533394
Quarters > 2 > ratios > ROE
-4.88848654431734
Quarters > 2 > ratios > ROA
-4.731241271057608
Quarters > 2 > ratios > FCF
-29293000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-563.3269230769231
Quarters > 2 > health Score
30
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
456000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
456000
Quarters > 3 > income Statement > operating Expenses
38505000
Quarters > 3 > income Statement > operating Income
-38049000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-31798000
Quarters > 3 > income Statement > net Income
-31798000
Quarters > 3 > income Statement > eps
-0.4905566911320207
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
64820235
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-38049000
Quarters > 3 > income Statement > operating Margin
-8344.07894736842
Quarters > 3 > income Statement > total Other Income Expense Net
6251000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
257068000
Quarters > 3 > balance Sheet > short Term Investments
484930000
Quarters > 3 > balance Sheet > receivables
781000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
754210000
Quarters > 3 > balance Sheet > property Plant Equipment
493000
Quarters > 3 > balance Sheet > total Assets
754797000
Quarters > 3 > balance Sheet > payables
6517000
Quarters > 3 > balance Sheet > short Term Debt
186000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
21420000
Quarters > 3 > balance Sheet > equity
733377000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-31798000
Quarters > 3 > cash Flow > depreciation
0
Quarters > 3 > cash Flow > change In Working Capital
4896000
Quarters > 3 > cash Flow > cash From Operations
-20662000
Quarters > 3 > cash Flow > capital Expenditures
209000
Quarters > 3 > cash Flow > cash From Investing
10905000
Quarters > 3 > cash Flow > cash From Financing
223414000
Quarters > 3 > cash Flow > net Change In Cash
213657000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.4905566911320207
Quarters > 3 > ratios > PB
3.5389741011785207
Quarters > 3 > ratios > ROE
-4.33583272996017
Quarters > 3 > ratios > ROA
-4.212788339116345
Quarters > 3 > ratios > FCF
-20871000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-45.76973684210526
Quarters > 3 > health Score
30
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
1139000
Annuals > 0 > income Statement > cost Of Revenue
32000
Annuals > 0 > income Statement > gross Profit
1139000
Annuals > 0 > income Statement > operating Expenses
115805000
Annuals > 0 > income Statement > operating Income
-114666000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-88039000
Annuals > 0 > income Statement > net Income
-88039000
Annuals > 0 > income Statement > eps
-1.408697815765546
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
62496725
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-114634000
Annuals > 0 > income Statement > operating Margin
-10067.251975417032
Annuals > 0 > income Statement > total Other Income Expense Net
26627000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
257068000
Annuals > 0 > balance Sheet > short Term Investments
484930000
Annuals > 0 > balance Sheet > receivables
781000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
754210000
Annuals > 0 > balance Sheet > property Plant Equipment
493000
Annuals > 0 > balance Sheet > total Assets
754797000
Annuals > 0 > balance Sheet > payables
6517000
Annuals > 0 > balance Sheet > short Term Debt
186000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
21420000
Annuals > 0 > balance Sheet > equity
733377000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-88039000
Annuals > 0 > cash Flow > depreciation
32000
Annuals > 0 > cash Flow > change In Working Capital
2906000
Annuals > 0 > cash Flow > cash From Operations
-78713000
Annuals > 0 > cash Flow > capital Expenditures
234000
Annuals > 0 > cash Flow > cash From Investing
-300764000
Annuals > 0 > cash Flow > cash From Financing
628279000
Annuals > 0 > cash Flow > net Change In Cash
248802000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-1.408697815765546
Annuals > 0 > ratios > PB
3.5382402529667556
Annuals > 0 > ratios > ROE
-12.004603362254338
Annuals > 0 > ratios > ROA
-11.663930831733566
Annuals > 0 > ratios > FCF
-78947000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-69.31255487269534
Annuals > 0 > health Score
29
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
204000
Annuals > 1 > income Statement > cost Of Revenue
17000
Annuals > 1 > income Statement > gross Profit
204000
Annuals > 1 > income Statement > operating Expenses
55653000
Annuals > 1 > income Statement > operating Income
-55449000
Annuals > 1 > income Statement > interest Expense
6904000
Annuals > 1 > income Statement > pretax Income
-48607000
Annuals > 1 > income Statement > net Income
-48607000
Annuals > 1 > income Statement > eps
-0.7294377841058648
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
66636252
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-55432000
Annuals > 1 > income Statement > operating Margin
-27180.88235294118
Annuals > 1 > income Statement > total Other Income Expense Net
6842000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
8266000
Annuals > 1 > balance Sheet > short Term Investments
179408000
Annuals > 1 > balance Sheet > receivables
92000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
194124000
Annuals > 1 > balance Sheet > property Plant Equipment
491000
Annuals > 1 > balance Sheet > total Assets
199301000
Annuals > 1 > balance Sheet > payables
3242000
Annuals > 1 > balance Sheet > short Term Debt
786000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
14511000
Annuals > 1 > balance Sheet > equity
184790000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-48607000
Annuals > 1 > cash Flow > depreciation
17000
Annuals > 1 > cash Flow > change In Working Capital
3439000
Annuals > 1 > cash Flow > cash From Operations
-45679000
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
-121195000
Annuals > 1 > cash Flow > cash From Financing
86997000
Annuals > 1 > cash Flow > net Change In Cash
-79877000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-0.7294377841058648
Annuals > 1 > ratios > PB
14.972331744358462
Annuals > 1 > ratios > ROE
-26.303912549380374
Annuals > 1 > ratios > ROA
-24.388738641552223
Annuals > 1 > ratios > FCF
-45679000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-223.91666666666666
Annuals > 1 > health Score
26
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
191000
Annuals > 2 > income Statement > cost Of Revenue
15000
Annuals > 2 > income Statement > gross Profit
176000
Annuals > 2 > income Statement > operating Expenses
35422000
Annuals > 2 > income Statement > operating Income
-35246000
Annuals > 2 > income Statement > interest Expense
1000
Annuals > 2 > income Statement > pretax Income
-35443000
Annuals > 2 > income Statement > net Income
-35443000
Annuals > 2 > income Statement > eps
-0.5318876577872357
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
66636252
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-35231000
Annuals > 2 > income Statement > operating Margin
-18453.403141361254
Annuals > 2 > income Statement > total Other Income Expense Net
-197000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
88143000
Annuals > 2 > balance Sheet > short Term Investments
55338000
Annuals > 2 > balance Sheet > receivables
303000
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
147208000
Annuals > 2 > balance Sheet > property Plant Equipment
506000
Annuals > 2 > balance Sheet > total Assets
147747000
Annuals > 2 > balance Sheet > payables
985000
Annuals > 2 > balance Sheet > short Term Debt
9155000
Annuals > 2 > balance Sheet > long Term Debt
6532000
Annuals > 2 > balance Sheet > total Liabilities
22570000
Annuals > 2 > balance Sheet > equity
125177000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-35443000
Annuals > 2 > cash Flow > depreciation
15000
Annuals > 2 > cash Flow > change In Working Capital
4439000
Annuals > 2 > cash Flow > cash From Operations
-29804000
Annuals > 2 > cash Flow > capital Expenditures
14000
Annuals > 2 > cash Flow > cash From Investing
-55352000
Annuals > 2 > cash Flow > cash From Financing
119692000
Annuals > 2 > cash Flow > net Change In Cash
34536000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.5318876577872357
Annuals > 2 > ratios > PB
22.102600182461636
Annuals > 2 > ratios > ROE
-28.31430694137102
Annuals > 2 > ratios > ROA
-23.988981163746136
Annuals > 2 > ratios > FCF
-29818000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-156.1151832460733
Annuals > 2 > health Score
26
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
10358000
Annuals > 3 > income Statement > cost Of Revenue
10000
Annuals > 3 > income Statement > gross Profit
10348000
Annuals > 3 > income Statement > operating Expenses
22954000
Annuals > 3 > income Statement > operating Income
-12606000
Annuals > 3 > income Statement > interest Expense
451000
Annuals > 3 > income Statement > pretax Income
-12839000
Annuals > 3 > income Statement > net Income
-12839000
Annuals > 3 > income Statement > eps
-0.19267290123099962
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
66636252
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-12378000
Annuals > 3 > income Statement > operating Margin
-121.70303147325738
Annuals > 3 > income Statement > total Other Income Expense Net
-233000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
53607000
Annuals > 3 > balance Sheet > short Term Investments
0
Annuals > 3 > balance Sheet > receivables
2000
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
58407000
Annuals > 3 > balance Sheet > property Plant Equipment
200000
Annuals > 3 > balance Sheet > total Assets
58692000
Annuals > 3 > balance Sheet > payables
1003000
Annuals > 3 > balance Sheet > short Term Debt
3015000
Annuals > 3 > balance Sheet > long Term Debt
12064000
Annuals > 3 > balance Sheet > total Liabilities
18440000
Annuals > 3 > balance Sheet > equity
40252000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-12839000
Annuals > 3 > cash Flow > depreciation
10000
Annuals > 3 > cash Flow > change In Working Capital
-1967000
Annuals > 3 > cash Flow > cash From Operations
-13654000
Annuals > 3 > cash Flow > capital Expenditures
97000
Annuals > 3 > cash Flow > cash From Investing
-97000
Annuals > 3 > cash Flow > cash From Financing
15446000
Annuals > 3 > cash Flow > net Change In Cash
1695000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.19267290123099962
Annuals > 3 > ratios > PB
68.73539657756137
Annuals > 3 > ratios > ROE
-31.896551724137932
Annuals > 3 > ratios > ROA
-21.875212976214815
Annuals > 3 > ratios > FCF
-13751000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-1.3275728905194053
Annuals > 3 > health Score
27
Valuation > metrics > PE
-0.5709390908029569
Valuation > metrics > PB
4.467809937772944
Valuation > final Score
35.32190062227056
Valuation > verdict
48.9% Overvalued
Profitability > metrics > ROE
-6.37074761176948
Profitability > metrics > ROA
-6.296152574771123
Profitability > metrics > Net Margin
-26.2953181272509
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.0614708504267476
Risk > metrics > Interest Coverage
-122.90625
Risk > final Score
-432
Risk > verdict
High
Liquidity > metrics > Current Ratio
68.85601187530925
Liquidity > metrics > Quick Ratio
68.70747154873825
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
34.470264647248186
Prev Valuations > 1
36.71489582466606
Prev Valuations > 2
44.610258988214795
Prev Profitabilities > 0
15
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-1190
Prev Risks > 1
38
Prev Risks > 2
36
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:35:23.923Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-14
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.57
Earnings History > 0 > eps Estimate
-0.5467
Earnings History > 0 > eps Difference
-0.0233
Earnings History > 0 > surprise Percent
-4.2619
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-08
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.54
Earnings History > 1 > eps Estimate
-0.4422
Earnings History > 1 > eps Difference
-0.0978
Earnings History > 1 > surprise Percent
-22.1167
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-13
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.45
Earnings History > 2 > eps Estimate
-0.374
Earnings History > 2 > eps Difference
-0.076
Earnings History > 2 > surprise Percent
-20.3209
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-03-28
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.46
Earnings History > 3 > eps Estimate
-0.45
Earnings History > 3 > eps Difference
-0.01
Earnings History > 3 > surprise Percent
-2.2222
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-12
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-0.3
Earnings History > 4 > eps Estimate
-0.42
Earnings History > 4 > eps Difference
0.12
Earnings History > 4 > surprise Percent
28.5714
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-08
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.28
Earnings History > 5 > eps Estimate
-0.4
Earnings History > 5 > eps Difference
0.12
Earnings History > 5 > surprise Percent
30
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-09
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.36
Earnings History > 6 > eps Estimate
-0.29
Earnings History > 6 > eps Difference
-0.07
Earnings History > 6 > surprise Percent
-24.1379
Earnings History > 7 > period
2023-12-31
Earnings History > 7 > report Date
2024-03-26
Earnings History > 7 > date
2023-12-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.3309
Earnings History > 7 > eps Estimate
-0.67
Earnings History > 7 > eps Difference
0.3391
Earnings History > 7 > surprise Percent
50.6119
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ARBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $73 - 富途资讯
1/21/2026
RBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $73 富途资讯
Read more →CG Oncology (NASDAQ:CGON) Sets New 52-Week High - Should You Buy? MarketBeat
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$70.7143
Analyst Picks
Strong Buy
5
Buy
4
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of CG Oncology, Inc. Common stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.57
EPS Estimate
-0.5467
EPS Difference
-0.0233
Surprise Percent
-4.2619%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.